Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetes Mellitus, Type 2, Obesity

In brief

Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.

Key facts

Study ID

NCT00478322

Run by

Incyte Corporation

People needed

24

Starts

2007-04-01

Expected to finish

2008-02-01

Last updated by the study team

2016-12-06

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have an established diagnosis of Type 2 Diabetes as determined by the investigator.
• Females will be postmenopausal for at least 1 year with documented FSH > 30 IU/L.

You may not qualify if…

• Hypertriglyceridemia > 500 mg/dL at screening.
• BMI > 40 kg/m2.
• Receiving thiazolidinediones, insulin, or exenatide within the 3 months prior to screening.
• History or clinical manifestations of Addison's disease, Cushing's Syndrome, or other disorders involving glucocorticoids or mineralocorticoids.
• Current treatment or treatment within 30 days or five half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational protocol.

Where it is running

• Study site — Chula Vista, California, United States
• Study site — The Bronx, New York, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.